Bacillus clausii as a Treatment of Small Intestinal Bacterial Overgrowth

  title={Bacillus clausii as a Treatment of Small Intestinal Bacterial Overgrowth},
  author={Maurizio Gabrielli and Ernesto Cristiano Lauritano and Emidio Scarpellini and Andrea Lupascu and Veronica Ojetti and Giovanni Battista Gasbarrini and Nicol{\'o} Gentiloni Silveri and Antonio Gasbarrini},
  journal={The American Journal of Gastroenterology},
Key Methodlated by the chi-squared test, and associations were estimated by the OR with 95 % CI. Statistical analyses used Epidat version 3.1. We found no evidence of associations between idiopathic achalasia and the NOS2A rs1060826 single nucleotide polymorphism (TT vs. carriers of allele G: OR = 0.88, 95 % CI 0.60 – 1.29, P = 0.52) ( Table 1 ). We observed, similar to the earlier study, a lower frequency of the genotype AA in achalasia than in controls (18 vs. 20 % ); however, in a pooled analysis…

SIBO: Dysbiosis Has A New Name

This article details the complex issue of small intestine bacterial overgrowth (SIBO), a condition in which abnormally large numbers of commensal bacteria (or other microorganisms) are present in the small intestine.

Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence

It is indicated that probiotics supplementation could effectively decontaminate SIBO, decrease H2 concentration, and relieve abdominal pain, but were ineffective in preventing SIBO.

Small Bowel Bacterial Overgrowth in Children

Owing to lack of established guidelines and few published interventional studies that assess the effectiveness of SBBO therapy, treatment of children with SBBO remains empiric and comprises antibiotic or probiotic therapy.

Antibiotic Treatment of Small Intestinal Bacterial Overgrowth: What Is the Evidence?

Analysis of the available data suggests that antibiotics, particularly rifaximin, may be effective in normalizing breath tests and improving gastrointestinal symptoms in patients with SIBO.

Is SIBO A Real Condition?

Testing and treating for SIBO can offer patients clinically significant relief, however, these tests and treatments must be applied with circumspection to prevent over-testing, over-treatment, squandering resources, or creating a fear around certain foods.

Probiotics, prebiotics & synbiotics in small intestinal bacterial overgrowth: Opening up a new therapeutic horizon!

The lack of an accepted “gold standard” for the clinical definition of SIBO, especially, in a non-classical clinical scenario, represents a major challenge for the clinician.

Small intestinal bacterial overgrowth syndrome.

Therapy for SIBO must be complex, addressing all causes, symptoms and complications, and fully individualised, it should include treatment of the underlying disease, nutritional support and cyclical gastro-intestinal selective antibiotics.

5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis

The microbial dysbiosis and the skewed negative correlation between Escherichia–Shigella and bacterial genera of Firmicutes are two characteristics of the inflamed mucosae of UC patients.



Small Intestinal Bacterial Overgrowth Recurrence After Antibiotic Therapy

GBT positivity recurrence rate was high after antibiotic treatment, and older age, history of appendectomy, and chronic use of PPIs were associated with GBT positive recurrence.

Presence of a protective allele for achalasia on the central region of the major histocompatibility complex.

The results confirm the association between achalasia and HLA-DQ1 allele and suggest that TNFa11 is a marker for a protective allele for the disease, present on the B7-DRB1*1501 (7.1) ancestral haplotype in this population.

Small Intestinal Bacterial Overgrowth: Diagnosis and Treatment

Breath tests (glucose and/or lactulose breath tests) have been proposed as a sensitive and simple tool for the diagnosis of bacterial overgrowth, being non-invasive and inexpensive compared to the gold standard represented by the culture of intestinal aspirates.

Association Between Achalasia and Nitric Oxide Synthase Gene Polymorphisms

Data suggest that NOS gene polymorphisms are not involved in the susceptibility to and nature of the clinical course of sporadic achalasia, and studies in a greater number of patients are required to analyze the tendency toward a higher prevalence of genotypes iNOS22*A/A and eNOS*4a4a.

Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics.

Although evidence from experimental animal studies consistently indicates that probiotics exert barrier-enhancing, antibacterial, immune-modulating, and anti-inflammatory effects, which all could be benefits in small intestinal bacterial overgrowth and intestinal failure, their role in human beings remains to be evaluated adequately.

Etiology and Pathogenesis of Achalasia: The Current Understanding

Current evidence suggests that the initial insult to the esophagus results in myenteric plexus inflammation, which leads to an autoimmune response in a susceptible population who may be genetically predisposed to achalasia.

Patients with achalasia lack nitric oxide synthase in the gastro‐oesophageal junction

It is suggested that the absence of NO synthase in the myenteric plexus of the gastro‐oesophageal junction explains the impaired function of the lower oesophageaal sphincter in achalasia.

Family occurrence of achalasia and diffuse spasm of the oesophagus.

The family coincidence of achalasia and oesophageal spasm supports a close relationship between the two diseases.